Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

Morten Orebo HolmströmDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark; ;National Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; Correspondence[email protected]

http://orcid.org/0000-0002-3764-8578 View further author information

Guy W. NovotnyDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; View further author information

Jesper PetersenDepartment of Hematology, Herlev University Hospital, Herlev, Denmark;

http://orcid.org/0000-0001-6116-5114 View further author information

Mia Aaboe-JørgensenNational Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; View further author information

Hans Carl HasselbalchDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark; ;Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; View further author information

Mads H. AndersenNational Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark; ;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;

http://orcid.org/0000-0002-2914-9605 View further author information

Signe Ledou NielsenDepartment of Pathology, Herlev University Hospital, Herlev, Denmark; View further author information

Daniel El FassiDepartment of Hematology, Herlev University Hospital, Herlev, Denmark; ;Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; ;Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen, Denmark

http://orcid.org/0000-0001-8226-1658 View further author information

Claudia SchöllkopfDepartment of Hematology, Herlev University Hospital, Herlev, Denmark;

http://orcid.org/0000-0003-1465-506X View further author information

show all